Novo Nordisk ROE 2006-2018 | NVO

Current and historical return on equity (ROE) values for Novo Nordisk (NVO) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Novo Nordisk ROE for the three months ending June 30, 2018 was 83.32%.
Novo Nordisk ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-06-30 $6.30B $7.86B 83.53%
2018-03-31 $6.11B $7.30B 83.00%
2017-12-31 $5.79B $7.57B 82.96%
2017-09-30 $5.73B $7.42B 84.54%
2017-06-30 $5.65B $7.16B 87.38%
2017-03-31 $5.69B $5.78B 90.46%
2016-12-31 $5.64B $6.73B 90.49%
2016-09-30 $5.59B $6.20B 88.77%
2016-06-30 $5.37B $6.47B 84.50%
2016-03-31 $5.09B $5.51B 82.31%
2015-12-31 $5.19B $6.99B 86.16%
2015-09-30 $5.08B $6.43B 83.64%
2015-06-30 $4.98B $5.80B 81.00%
2015-03-31 $5.03B $4.87B 78.79%
2014-12-31 $4.72B $7.18B 70.33%
2014-09-30 $4.74B $6.76B 69.51%
2014-06-30 $4.72B $6.74B 68.77%
2014-03-31 $4.61B $6.17B 68.59%
2013-12-31 $4.49B $7.58B 67.16%
2013-09-30 $4.38B $6.95B 67.04%
2013-06-30 $4.20B $6.20B 66.63%
2013-03-31 $3.94B $5.99B 64.56%
2012-12-31 $3.70B $7.02B 61.39%
2012-09-30 $3.53B $5.99B 58.56%
2012-06-30 $3.36B $5.42B 54.13%
2012-03-31 $3.24B $5.71B 48.73%
2011-12-31 $3.16B $7.00B 46.43%
2011-09-30 $3.06B $6.73B 45.62%
2011-06-30 $2.94B $7.13B 45.21%
2011-03-31 $2.77B $6.38B 44.97%
2010-12-31 $2.62B $6.59B 42.96%
2010-09-30 $2.35B $5.93B 38.39%
2010-06-30 $2.23B $5.75B 35.31%
2010-03-31 $2.15B $6.12B 33.40%
2009-12-31 $2.03B $6.69B 32.40%
2009-09-30 $1.99B $6.70B 31.89%
2009-06-30 $1.98B $6.23B 32.00%
2009-03-31 $1.76B $5.49B 27.73%
2008-12-31 $1.72B $6.50B 26.24%
2008-09-30 $1.50B $6.50B 23.37%
2008-06-30 $1.36B $6.94B 21.58%
2008-03-31 $1.69B $6.28B 27.76%
2007-12-31 $1.56B $5.92B 26.65%
2007-09-30 $1.66B $6.14B 29.58%
2007-06-30 $1.56B $6.06B 29.46%
2007-03-31 $1.19B $5.22B 23.83%
2006-12-31 $1.09B $5.06B 22.71%
2006-09-30 $1.00B $4.84B 21.41%
2006-06-30 $1.00B $4.86B 22.00%
2006-03-31 $0.99B $4.35B 22.80%
2005-12-31 $1.02B $4.62B 23.17%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $105.487B $16.962B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $373.058B 17.49
Pfizer (PFE) United States $264.903B 15.51
Novartis AG (NVS) Switzerland $202.059B 17.27
Merck (MRK) United States $195.069B 17.23
AbbVie (ABBV) United States $133.211B 13.01
Eli Lilly (LLY) United States $120.201B 22.25
Sanofi (SNY) France $111.785B 14.15
GlaxoSmithKline (GSK) United Kingdom $101.355B 13.53
AstraZeneca (AZN) United Kingdom $99.315B 10.92
Bristol-Myers Squibb (BMY) United States $88.755B 16.07